Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.82 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243291 | 0.90 | SRD5A2 (1.00) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL7169748 | 0.90 | SRD5A2 (1.00) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL7193910 | 0.86 | SRD5A1 (0.62) | SRD5A2SRD5A1KDM4EALDH1A1HPGD | |
| SCHEMBL5701857 | 0.86 | SRD5A2 (0.76) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL5702163 | 0.84 | SRD5A2 (0.76) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL5702136 | 0.84 | SRD5A1 (0.58) | SRD5A2SRD5A1KDM4EALDH1A1HPGD | |
| SCHEMBL7174812 | 0.83 | SRD5A2 (0.88) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL335983 | 0.82 | SRD5A1 (0.70) | SRD5A2SRD5A1KDM4EALDH1A1HPGD | |
| SCHEMBL5829229 | 0.81 | SRD5A2 (0.82) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL7159304 | 0.81 | SRD5A2 (0.82) | SRD5A2SRD5A1KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302460-B1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | OREAL (FR) | 2006-08-02 | — | — | EP | claimed |
| US-6596753-B2 | Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen | SOCIETE L'OREAL S.A. (FR) | 2003-07-22 | — | — | US | claimed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | claimed |
| US-6596753-B2 | Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen | SOCIETE L'OREAL S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | disclosed |
| US-6448285-B1 | DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA | SOCIETE L'OREAL S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | CYP17A1, SRD5A1, SRD5A2 | SRD5A2 3/4885SRD5A1 2/4885KDM4E 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.